HT-6184 is under clinical development by Halia Therapeutics and currently in Phase II for Acute Inflammation. According to GlobalData, Phase II drugs for Acute Inflammation does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HT-6184 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HT-6184 overview
HT-6184 is under development for the treatment of thermal hyperalgesia and mechanical allodynia, Alzheimer’s disease, myelodysplastic syndrome (MDS), chronic inflammation, acute myeloid leukemia (AML), post-procedure acute Inflammation and pain and unspecified ophthalmological disorder. It acts by targeting NEK7/NLRP3. It is administered through oral route.
It was under development for neuroinflammation.
Halia Therapeutics overview
Halia Therapeutics (Halia) is a preclinical-stage biopharmaceutical company. It is headquartered in Lehi, Utah, the US.
For a complete picture of HT-6184’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.